Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
Sponsor: TG Therapeutics, Inc.
A PHASE1 clinical study on Hodgkin's Lymphoma, this trial is completed. The trial is conducted by TG Therapeutics, Inc. and has accumulated 12 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TG Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .